<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Otsuka Holdings Co., Ltd. Otsuka Group News RSS</title>
    <link>http://www.otsuka.com</link>
    <description>Otsuka Holdings Co., Ltd. Otsuka Group News RSS</description>
    <atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="http://www.otsuka.com/en/group_news/rss.php" type="application/rss+xml" rel="self"/>
    <pubDate>Thu, 13 Aug 2026 09:00:00 +0900</pubDate>
    <lastBuildDate>Thu, 13 Aug 2026 09:00:00 +0900</lastBuildDate>
    <ttl>60</ttl>
    <item>
      <title>Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3  REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer</title>
      <link>https://www.taiho.co.jp/en/release/2026/20260813.html</link>
      <description/>
      <pubDate>Thu, 13 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1617</news_id>
    </item>
    <item>
      <title>Otsuka Sponsors the 20th Asian Games Aichi-Nagoya 2026 Supporting Conditioning and Performance with the Global Brand POCARI SWEAT</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260804_1.html</link>
      <description/>
      <pubDate>Tue, 04 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1614</news_id>
    </item>
    <item>
      <title>Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260804_2.html</link>
      <description/>
      <pubDate>Tue, 04 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1615</news_id>
    </item>
    <item>
      <title>Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologies Optimizing Manufacturing Processes to Enable Stable Production of High-Quality ADCs</title>
      <link>https://www.taiho.co.jp/en/release/2026/20260803.html</link>
      <description/>
      <pubDate>Mon, 03 Aug 2026 09:00:00 +0900</pubDate>
      <news_id>1611</news_id>
    </item>
    <item>
      <title>The Results Suggest the Potential Usefulness of S-Equol in Women with Severe Symptoms of PMS and PMDD New Findings Contribute to Advancing Support for Women’s Health</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260730_1.html</link>
      <description/>
      <pubDate>Thu, 30 Jul 2026 09:00:00 +0900</pubDate>
      <news_id>1613</news_id>
    </item>
    <item>
      <title>Otsuka Foods to Launch Micro Magic French Fries: Black Pepper A New Flavor for Adults, Microwavable in the Box, Perfect with Drinks In Stores across Japan from August 24, 2026</title>
      <link>https://www.otsukafoods.co.jp/en/news/20260729.html</link>
      <description/>
      <pubDate>Wed, 29 Jul 2026 09:00:00 +0900</pubDate>
      <news_id>1612</news_id>
    </item>
    <item>
      <title>Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026（Link to Otsuka America Pharmaceutical website）</title>
      <link>https://otsuka-us.com/news/otsuka-present-pivotal-two-year-egfr-results-phase-3-visionary-trial-voyxactr-sibeprenlimab</link>
      <description/>
      <pubDate>Mon, 27 Jul 2026 09:00:00 +0900</pubDate>
      <news_id>1610</news_id>
    </item>
    <item>
      <title>Otsuka Launches POCARI SWEAT ION WATER Powder Stick Packet to Make 500ml Easy Water and Ion Replenishment for Day-to-Day Situations: Ideal for Use with Reusable Bottles</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260727_2.html</link>
      <description/>
      <pubDate>Mon, 27 Jul 2026 09:00:00 +0900</pubDate>
      <news_id>1609</news_id>
    </item>
    <item>
      <title>Otsuka Receives FDA Approval for First-in-Class SIMTRIYO (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260727_1.html</link>
      <description/>
      <pubDate>Mon, 27 Jul 2026 09:00:00 +0900</pubDate>
      <news_id>1608</news_id>
    </item>
    <item>
      <title>Announcement of Price Revisions for Specified Products</title>
      <link>https://www.otsuka.co.jp/en/company/newsreleases/2026/20260723_1.html</link>
      <description/>
      <pubDate>Thu, 23 Jul 2026 09:00:00 +0900</pubDate>
      <news_id>1607</news_id>
    </item>
  </channel>
</rss>
